Exact Sciences Corporation (EXAS)
NEUTRALFundamental
39
Precio
$-
Capitalización Bursátil
$20.03B
Parte 1 · Cuánto vale la empresa
Resumen
Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. It offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer; Cologuard Plus Tests; Cancerguard Test; and Genetic Testing. The company also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; Oncodetect Test;OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Riskguard Test, a hereditary cancer test to understand their inherited risk of cancer. Its pipeline focus on advancing screening and diagnostic products, including risk assessment, screening and prevention, early disease diagnosis, adjuvant and/or neoadjuvant disease treatment, metastatic disease treatment selection, and recurrence monitoring. The company has license agreements with MAYO Foundation for Medical Education and Research, and Johns Hopkins University, as well as Freenome Holdings, Inc. Exact Sciences Corporation was incorporated in 1995 and is headquartered in Madison, Wisconsin.
No editorial profile for this company yet
Direct competitors
Who this company fights with for the same customers
No editorial profile for this company yet
No competitor list for this company yet.
Balance y Liquidez
Ingresos
$3.25B
Ejercicio cerrado el 31/12/2025
Beneficio Neto
$-208M
Ejercicio cerrado el 31/12/2025
Flujo de Caja Libre
$282M
Patrimonio Neto Total
$2.40B
Pasivo Total
$2.53B
Ratio de Liquidez
2.43
Cobertura de Intereses
-
Deuda/EBITDA
35.47
Beneficio Por Acción
Ingresos y Beneficio Neto
Flujo de Caja Libre
Desglose de Ingresos
Estado histórico
Márgenes en el tiempo
La deuda en el tiempo
Cuánto pesa la deuda
Cuadro de crecimiento
Crecimiento — Ingresos
Estimación de Valor Justo
Valor Justo
$76.95
Precio Actual
-
Margen de Seguridad
-
Rango de Valor Justo
$50.02 - $103.88
Métodos de Estimación
Métricas de Valoración
Ratio P/E
-
ROE
-8.7%
Ratio P/B
8.34
P/FCF
-
Margen Bruto
69.7%
ROIC
-4.8%
Radar de Rentabilidad
Value Creation (Economic Moat)
ROIC
-4.8%
WACC
7.1%
ROIC − WACC
-11.9 pp
ROIC is below the cost of capital — the company is destroying value for every dollar invested.
Criterios de Análisis Fundamental
Superado (7)
- Price CAGR 22.89%
- Gross Margin 69.7%
- Debt/Equity ratio
- Positive Free Cash Flow
- Current Ratio
- Revenue Growth 5Y 16.8%
- Net Margin Trend -6.4% vs -37.3%
Fallido (9)
- ROIC -4.8%
- P/B Ratio 8.34
- CapEx intensity
- Debt/EBITDA
- DCF valuation (Unknown)
- ROE -8.5%
- Analyst Consensus 28% Buy
- Earnings Surprise avg -111.7%
- Piotroski F-Score 2/9
No disponible (11)
- EPS data insufficient
- P/FCF NaN
- Dividend Payout NaN%
- Operating Margin NaN%
- Interest Coverage
- Return on Tangible Assets
- Low reliance on intangibles
- Price below Graham Number
- PEG Ratio (need PE > 0 and growth > 0)
- Earnings Quality (OCF/Net Income)
- Share Dilution (missing shares data)
Piotroski F-Score
Preocupaciones financieras graves
Calidad de los Beneficios
Baja calidad: investigue la contabilidad
Dilución de Acciones
Recomprando acciones. Favorable para el accionista
Gobernanza
Riesgo de Auditoría
1
Riesgo del Consejo
2
Riesgo de Compensación
3
Riesgo de Derechos del Accionista
4
Parte 2 · El precio y el momento de entrar
Esta parte no sirve para saber si la empresa vale: sirve para elegir cuándo comprarla, una vez que los fundamentales te han convencido. Dentro: análisis técnico, potencial, caídas históricas, exposición gamma.
Latest News
Recent headlines for EXAS, sourced from Markets Gazette.
- 2/23/2026POSITIVEAbbott Laboratories Kicks Off Bond Sale for Exact Sciences Deal
Abbott Laboratories is launching a significant bond sale, in as many as eight parts, to fund its approximately $21 billion acquisition of cancer-screening company Exact Sciences Corp. This move signals Abbott's strong commitment to finalizing a strategic deal that will bolster its diagnostics portfolio. For shareholders of Exact Sciences, this development is a clear positive catalyst. Acquisitions of this magnitude are typically executed at a premium to the target's current market price, suggesting an immediate upward revaluation of the stock. Abbott's financing action validates the technology and growth potential of Exact Sciences, turning the company's intrinsic value into a tangible gain for investors as the deal progresses.
via Markets Gazette